Comprehensive Biomarker Center GmbH Accredited by German DAkkS
News May 22, 2015
As of April 1, 2015 the Comprehensive Biomarker Center GmbH has been accredited according to DIN EN ISO/IEC 17025:2005 from the national accreditation body for the Federal Republic of Germany (DAkkS). The independent governmental institution has acknowledged the high quality standard of CBC’s biomarker services on the Agilent microarray platform.
Based in Heidelberg, Germany, CBC has been accredited for its expertise in the extraction of total RNA from body fluids and the analysis of microRNA & mRNA using the Agilent microarray platform.
Jochen Kohlhaas, chief executive officer at CBC GmbH, commented: “I am very proud that CBC has received DIN EN ISO/IEC 17025:2005 accreditation. This reflects our commitment to our clients and the dedication of our laboratory staff. It is a strong endorsement of the high quality of our services.”
“The potential of microRNA biomarkers in disease detection and monitoring, as well as companion diagnostics is increasingly recognized. As an accredited biomarker company, we provide reliable and continuously high quality in our methods, technologies and data quality of the analysis service. Having DIN EN ISO/IEC 17025:2005 accreditation demonstrates CBC’s competency to conduct testing to the highest standards and the strength of our quality management system” said Karoly Nikolich, chairman of CBC’s board and renowned biotechnology expert.” The accreditation allows customers to compare the quality of service providers in the microRNA Biomarker field.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.